Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Pratibha Singh

Assistant researcher

Default user image.

Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes

Author

  • Tiinamaija Tuomi
  • Cecilia L F Nagorny
  • Pratibha Singh
  • Hedvig Bennet
  • Qian Yu
  • Ida Alenkvist
  • Bo Isomaa
  • Bjarne Östman
  • Johan Söderström
  • Anu Katriina Pesonen
  • Silja Martikainen
  • Katri Räikkönen
  • Tom Forsén
  • Liisa Hakaste
  • Peter Almgren
  • Petter Storm
  • Olof Asplund
  • Liliya Shcherbina
  • Malin Fex
  • João Fadista
  • Anders Tengholm
  • Nils Wierup
  • Leif Groop
  • Hindrik Mulder

Summary, in English

Type 2 diabetes (T2D) is a global pandemic. Genome-wide association studies (GWASs) have identified >100 genetic variants associated with the disease, including a common variant in the melatonin receptor 1 b gene (MTNR1B). Here, we demonstrate increased MTNR1B expression in human islets from risk G-allele carriers, which likely leads to a reduction in insulin release, increasing T2D risk. Accordingly, in insulin-secreting cells, melatonin reduced cAMP levels, and MTNR1B overexpression exaggerated the inhibition of insulin release exerted by melatonin. Conversely, mice with a disruption of the receptor secreted more insulin. Melatonin treatment in a human recall-by-genotype study reduced insulin secretion and raised glucose levels more extensively in risk G-allele carriers. Thus, our data support a model where enhanced melatonin signaling in islets reduces insulin secretion, leading to hyperglycemia and greater future risk of T2D. The findings also imply that melatonin physiologically serves to inhibit nocturnal insulin release.

Department/s

  • Diabetes - Molecular Metabolism
  • Diabetes and Celiac Unit
  • Genomics, Diabetes and Endocrinology
  • Neuroendocrine Cell Biology
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2016-06-14

Language

English

Pages

1067-1077

Publication/Series

Cell Metabolism

Volume

23

Issue

6

Document type

Journal article

Publisher

Cell Press

Topic

  • Cell and Molecular Biology
  • Endocrinology and Diabetes

Keywords

  • gene targeting
  • insulin
  • islets
  • recall-by-genotype
  • RNA sequencing

Status

Published

Research group

  • LUDC (Lund University Diabetes Centre)
  • Diabetes - Molecular Metabolism
  • Diabetes and Celiac Unit
  • Genomics, Diabetes and Endocrinology
  • Neuroendocrine Cell Biology

ISBN/ISSN/Other

  • ISSN: 1550-4131